TAK
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$18.16
장중 · Vol 187.7K · 52주 $12.99–$18.90 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $18.00 · Aug 31, 2026
TAK 가격 추세
종가
$18.00
시가
$17.99
고가
$18.06
저가
$17.95
30초 브리핑
TAK 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 87%
연중 고점권입니다. 추세 강도와 돌파 실패 위험을 함께 확인하세요.
Forward P/E 33.9배
업종 피어 비교 전에는 고평가·저평가를 단정하기 어렵습니다.
20일 평균의 0.6배
거래 참여가 낮아 현재 움직임의 신뢰도가 제한적입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
TAK 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
1-1, Nihonbashi-Honcho 2-chome · Chuo, Japan · 직원 47,029명
시가총액
$57.42B
Trailing P/E
—
최근 12개월 이익 기준
Forward P/E
33.9
EPS (TTM)
$-0.33
배당 수익률
3.43%
배당성향
80.0%
지속 가능성 점검
베타
0.10
시장보다 방어적
ROE
-2.3%
P/B
1.20
EV/EBITDA
4.1
52주 범위
$12.99 – $18.90
현재 위치 87%
거래량
1.39M
20일 평균 2.25M · 0.6배
애널리스트 의견
매수 100%
총 3명 · 0m
DITM LEAPS Analysis
TAK 장기 DITM 콜옵션을 진입 적합도 순으로 비교
해당 종목의 옵션 데이터가 없습니다.
재무제표
TAK 연간 손익·현금흐름·재무상태
매출 성장률
-1.7%
최근 연간 YoY
EPS 성장률
-243.9%
최근 연간 YoY
영업이익률
10.3%
최근 연간
FCF 마진
13.9%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| 매출 | $4.51T-1.7% | $4.58T+7.5% | $4.26T+5.9% | $4.03T |
| 매출총이익 | $2.93T-2.2% | $3.00T+5.8% | $2.84T+1.9% | $2.78T |
| 영업이익 | $464.45B-0.4% | $466.37B+50.5% | $309.90B-47.3% | $587.81B |
| 순이익 | -$152.39B-241.2% | $107.93B-25.1% | $144.07B-54.6% | $317.02B |
| 희석 EPS | $-48.38-243.9% | $33.62-26.3% | $45.58-54.9% | $100.97 |
| EBITDA | $726.89B-32.3% | $1.07T+19.3% | $900.33B-22.1% | $1.16T |
| 영업현금흐름 | $1.04T-1.5% | $1.06T+47.6% | $716.34B-26.7% | $977.16B |
| 잉여현금흐름 | $626.77B-7.5% | $677.56B+187.6% | $235.61B-31.4% | $343.47B |
| 총자산 | $15.51T+8.9% | $14.25T-5.7% | $15.11T+8.2% | $13.96T |
| 총부채 | $4.88T+8.1% | $4.52T-6.8% | $4.84T+10.5% | $4.38T |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
TAK 실적·배당 일정
매출 하단
$1104.20B
매출 상단
$1220.30B
배당 지급일
2026-07-06
57일 전
실적 발표일
2026-10-29
D-58
매출 컨센서스
$1160.63B
배당락일
2026-03-31
154일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Mar 31, 2025 | $0.3390 |
| Sep 30, 2024 | $0.3260 |
| Mar 27, 2024 | $0.2920 |
뉴스
TAK 관련 최신 기사
규제·법률Why Is Protagonist Therapeutics (PTGX) In Focus After MIMRYLO FDA Approval?
Protagonist Therapeutics (NasdaqGM: PTGX) reported U.S. FDA approval of MIMRYLO (rusfertide) as a first in class hepcidin mimetic peptide for adults with polycythemia vera. The approval makes MIMRYLO the only FDA approved hepcidin mimetic therapy available for this rare blood cancer. The decision triggers milestone payments from partner Takeda to Protagonist Therapeutics, linked to clinical and commercial progress for MIMRYLO. This approval highlights how drug developers using advanced...
Simply Wall St. · Sep 1, 2026
제품·기술Chris Benecchi Named Inventiva’s New Chief Operating Officer
By Karen Roman Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company). Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for […] The post Chris Benecchi Named Inventiva’s New Chief Operating Officer appeared first on ExecEdge.
Exec Edge · Aug 31, 2026
- 일반
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index decreasing 0.5% a
MT Newswires · Aug 31, 2026
규제·법률Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment
Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV. The approval marks the company’s second FDA-approved medicine this year, following the M
MarketBeat · Aug 31, 2026
규제·법률Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
On Friday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s (NYSE:TAK) MIMRYLO (rusfertide) for polycythemia vera, a type of blood cancer. How MIMRYLO Combats Polycythemia Vera Polycythemia vera forces the human body to overproduce red blood cells. This harmful overproduction dramatically increases blood thickness. Increased viscosity places patients at high risk for life-threatening thrombotic events, which include severe complications like strokes, pulmonar
Benzinga · Aug 31, 2026
- 실적
FDA OKs Takeda, Protagonist drug for rare blood cancer
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
BioPharma Dive · Aug 31, 2026
- 일반
How Expanded Nuvaxovid Royalties and Partner-led Execution Could Shape Novavax’s (NVAX) Investment Narrative
Novavax reported that partners Sanofi and Takeda have secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026–2027 vaccination season across the U.S., European Union, Japan, and other major markets. These approvals allow Novavax to participate in the upcoming COVID-19 vaccination season primarily through royalties and milestones, while its partners shoulder the commercial execution and infrastructure burden. We'll now examine how Novavax’s...
Simply Wall St. · Aug 29, 2026
실적NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open
Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.
Stocktwits · Aug 28, 2026
실적KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
Zacks · Aug 24, 2026
실적Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
Zacks · Aug 24, 2026
홀더
TAK 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
3.3%
기관 보유 (유동주식)
3.3%
내부자 보유
0.1%
기관 수
453
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Capital Research Global Investors | 19.30M | $346.97M | 0.6% | 1.0% | Jun 30, 2026 |
| FMR, LLC | 9.60M | $172.60M | 0.3% | 34.9% | Jun 30, 2026 |
| Morgan Stanley | 6.99M | $125.77M | 0.2% | 8.1% | Jun 30, 2026 |
| Adage Capital Partners GP L.L.C. | 6.05M | $108.79M | 0.2% | -5.8% | Jun 30, 2026 |
| Goldman Sachs Group Inc | 5.13M | $92.15M | 0.2% | -8.8% | Jun 30, 2026 |
| Brandes Investment Partners L.P. | 4.54M | $81.62M | 0.1% | 2.5% | Jun 30, 2026 |
| Blackrock Inc. | 3.69M | $66.31M | 0.1% | 16.1% | Jun 30, 2026 |
| Arrowstreet Capital, Limited Partnership | 3.73M | $67.12M | 0.1% | 19.8% | Jun 30, 2026 |
| Renaissance Technologies, LLC | 2.57M | $46.17M | 0.1% | -14.1% | Jun 30, 2026 |
| Qube Research & Technologies Ltd | 2.21M | $39.69M | 0.1% | 100.0% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.
